NICE has recommended extended funding on the NHS for AstraZeneca’s high potassium drug Lokelma in final draft guidance.

HAMMOND | A local group focused on patient safety is taking steps to make sure Northwest Indiana residents always have their medication information with them.

AZ’s drug will go head to head with Veltassa (patiromer), marketed by Vifor Pharma group member Relypsa, which is already approved for hyperkalaemia in the US and Europe.